Table 6.

Concentration of APOA1 in high-density lipoprotein subspecies expressed as a percentage of total APOA1 concentration by treatment arm at baseline and week 12 visits

Variable	Visit	1 mg/d	5 mg/d	15 mg/d	Placebo	P, 5 mg/d vs placebo	P, any effect
		N = 13	N = 13	N = 13	N = 13
APOA1 concentration of HDL that contains α2-macroglobulin/total plasma apoA1 concentration, %	Baseline	2.16 ± 0.64	2.24 ± 0.65	2.65 ± 0.50	2.07 ± 0.55
	Week 12	1.93 ± 0.76	1.95 ± 0.61	2.51 ± 0.56	2.22 ± 0.57	.085	.095
APOA1 concentration of HDL that contains APOC1/total plasma apoA1 concentration, %	Baseline	14.5 ± 2.94	15.8 ± 5.06	17.1 ± 3.54	13.5 ± 2.76
	Wk 12	13.5 ± 2.78	15.9 ± 3.76	17.1 ± 3.52	13.7 ± 2.49	.376	.104
APOA1 concentration of HDL that contains APOC3/total plasma APOA1 concentration, %	Baseline	4.97 ± 1.22	5.42 ± 1.97	4.38 ± 1.13	4.78 ± 2.15
	Wk 12	3.87 ± 1.11	4.24 ± 1.74	4.04 ± 1.38	4.32 ± 2.10	.498	.720
APOA1 concentration of HDL that contains complement C3/total plasma APOA1 concentration, %	Baseline	2.28 ± 0.83	2.09 ± 0.83	2.40 ± 0.87	2.23 ± 1.13
	Wk 12	1.90 ± 0.68	1.69 ± 0.61	1.60 ± 0.44	1.85 ± 0.86	.659	.646
APOA1 concentration of HDL that contains APOE/total plasma APOA1 concentration, %	Baseline	16.6 ± 5.89	13.3 ± 3.81	13.7 ± 5.11	12.1 ± 2.57
	Wk 12	15.1 ± 6.39	11.5 ± 3.31	14.4 ± 4.94	12.3 ± 2.77	.049	.052
APOA1 concentration of HDL that contains plasminogen/total plasma APOA1 concentration, %	Baseline	3.99 ± 1.46	2.88 ± 0.77	3.21 ± 1.32	3.33 ± 1.48
	Wk 12	3.51 ± 1.47	2.47 ± 0.66	2.55 ± 0.56	3.09 ± 1.04	.180	.241

Changes from baseline and 95% CI at baseline and week 12 by treatment arm. P values, extracted from an ANCOVA framework, are for comparison of the 5 mg/day arm with the placebo group and for the test of any difference between groups in average change over 12-week follow-up.

Abbreviations: ANCOVA, analysis of covariance; HDL, high-density lipoprotein.